Association of Contemporary Sensitive Troponin I Levels at Baseline and Change at 1 Year With Long-Term Coronary Events Following Myocardial Infarction or Unstable Angina Results From the LIPID Study (Long-Term Intervention With Pravastatin in Ischaemic Disease)

Grants

Funding Acknowledgements

This study was supported by research grants from the National Health and Medical Research Council Australia (NHMRC 512657 and 490968). The LIPID study was supported by Bristol-Myers Squibb and conducted under the auspices of the National Heart Foundation of Australia. Dr. White has received research grants from sanofi-aventis, Eli Lilly, The Medicines Company, National Institutes of Health (NIH), Pfizer, Roche, Johnson & Johnson, Schering-Plough, Merck Sharpe & Dohme, AstraZeneca, GlaxoSmithKline, Daiichi-Sankyo Pharma Development, and Bristol-Myers Squibb; and has served on advisory boards for Merck Sharpe & Dohme, Roche, and Regado Biosciences. Dr. Tonkin has received research grants from AstraZeneca, Bristol-Myers Squibb, Merck Sharpe & Dohme, and the NIH; and has served on advisory boards for AstraZeneca, Merck Sharpe & Dohme, and Pfizer. Dr. West has received research grants from Merck Sharpe & Dohme, AstraZeneca, GlaxoSmithKline, and Bristol-Myers Squibb. Dr. Nestel has served on advisory boards for and has received consulting fees from AstraZeneca and Merck Sharpe & Dohme. Dr. Keech has received research support from and has served on speakers bureaus for Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Roche Diagnostics, and Solvay. Dr. Blankenberg has received research grants from Boehringer Ingelheim, Bayer, Abbott Diagnostics, Siemens, and Thermo Fisher; has received lecture fees from AstraZeneca, Bayer, Boehringer Ingelheim, Siemens, and Abbott Diagnostics; and has served on advisory boards for Boehringer Ingelheim, Bayer, and Thermo Fisher.